KLRD1 and neoplasm: Furthermore, vaccines targeting KLRD1 can activate specific immune responses, improving the body's immune surveillance against tumors In iNKT cell therapy, introducing single-chain antibodies targeting KLRD1 into T cells enables them to more effectively recognize and attack tumor cells expressing the relevant ligands 40, 41.